PNPLA3 and fatty liver disease: In a recent study, the use of liver-targeted ASO to silence patatin-like phospholipase domain containing 3 (PNPLA3) in a knock-in mouse model with the human PNPLA3 I148M variant resulted in reduced liver steatosis, inflammation, and fibrosis, alongside decreased inflammatory markers [117].